. Author manuscript; available in PMC: 2012 Apr 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Apr;56(4):344–348. doi: 10.1097/QAI.0b013e31820cf029

Table 2.

Associations of Pre-Therapy RT Mutations with Virologic Failure^a

		Controls^b	Failures
Domain	Mutation	N=144^c	N=53^d	p-value^e

		% (N)	% (N)
Polymerase	E6D	3 (4)	12 (6)^f	0.023
	K103R	1 (2)	8 (4)	0.046
	Q174K	1 (2)	10 (5)	0.015

Connection	Q334H	6 (9)	16 (8)	0.045

Mutations with p < 0.05 listed; not corrected for multiple comparisons.

Controls did not reach protocol-defined virologic failure.

For the control group, subtype C sequences (N=3) were excluded for analyses of codon 334 because they differed from subtype B consensus.

For the failure group, subtype C sequences (N=4) were excluded from analysis at codon 334 because they differed from subtype B consensus. One CRF AE sequence was excluded at codon 174 for the same reason.

Fisher’s exact test (two-sided) not corrected for multiple comparisons. No significant associations were found after correction for multiple comparisons (Bonferroni).

Total N=52, missing first 16 amino acids for one sample.